Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts

Vartan Pahalyants; William S Murphy; Nikolai Klebanov; Chenyue Lu; Nicholas Theodosakis; R Monina Klevens; Hossein Estir; Evelyn Lilly; Maryam Asgari; Yevgeniy R Semenov

doi:10.1016/j.jaad.2021.08.065

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts

J Am Acad Dermatol. 2022 Jan;86(1):252-255. doi: 10.1016/j.jaad.2021.08.065. Epub 2021 Sep 10.

Affiliations

¹ Department of Dermatology, Massachusetts General Hospital, Boston; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Massachusetts General Hospital, Boston.
³ Massachusetts Department of Public Health, Bureau of Infectious Disease and Laboratory Sciences, Boston.
⁴ Laboratory of Computer Science, Massachusetts General Hospital, Boston; Department of Medicine, Massachusetts General Hospital, Boston.
⁵ Department of Dermatology, Massachusetts General Hospital, Boston. Electronic address: ysemenov@mgh.harvard.edu.

No abstract available

Keywords: COVID-19; IL-12/22; IL-17A; IL-4A; TNF; atopic dermatitis; autoimmune diseases; biologics; psoriasis; systemic immunosuppression; systemic lupus erythematosus.

MeSH terms

Biological Products* / adverse effects
COVID-19* / epidemiology
COVID-19* / mortality
Humans
Immunosuppressive Agents* / adverse effects
Massachusetts / epidemiology
Retrospective Studies

Substances

Biological Products
Immunosuppressive Agents

Grants and funding

T32 AR007098/AR/NIAMS NIH HHS/United States